Research programme: aziridine aldehyde-based macrocycle therapeutics - Encycle Therapeutics

Drug Profile

Research programme: aziridine aldehyde-based macrocycle therapeutics - Encycle Therapeutics

Alternative Names: Cyclic peptidomimetic - Encycle Therapeutics; Integrin α 4 beta 7 inhibitors- Encycle Therapeutics; Nacellins - Encycle Therapeutics; SMURF2 modulators - Encycle Therapeutics

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Encycle Therapeutics
  • Developer Encycle Therapeutics; MaRS Innovation; University of Montreal
  • Class Macrocyclic compounds; Peptidomimetics
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Fibrosis; Inflammatory bowel diseases

Most Recent Events

  • 21 Nov 2016 Early research in Cancer in Canada (unspecified route)
  • 10 Nov 2014 Encycle Therapeutics, the University of Montreal and MaRS Innovation collaborates to develop nacellins in Canada for Inflammatory bowel disease
  • 12 Aug 2014 Encycle Therapeutics enters into a collaboration agreement with the University of Toronto and University of Sherbrooke to synthesise drug-like peptides and develop and validate the Encycle's platform technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top